Management of Type 2 Diabetes

Introduction to Tirzepatide

Tirzepatide is a glucose-lowering medication recommended by the American Diabetes Association for type 2 diabetes management, with injectable GLP-1 RAs showing greater efficacy than oral formulations 1, 2
The cost-effectiveness of injectable GLP-1 RAs, such as tirzepatide, is higher compared to oral formulations, with a cost of approximately $875,000 per QALY vs. metformin 2

The American Diabetes Association suggests considering injectable tirzepatide as a first-line treatment for patients with type 2 diabetes and overweight/obesity, particularly when significant weight loss and glycemic control are priorities 3
The European Association for the Study of Diabetes and the American College of Cardiology recommend first-line or add-on therapy with tirzepatide for patients with established cardiovascular disease or high cardiovascular risk 4
Tirzepatide is considered for patients with type 2 diabetes not adequately controlled on metformin, with overweight or obesity, established cardiovascular disease or high risk factors, and need for significant HbA1c reduction, as suggested by the American Medical Association 1

Tirzepatide offers superior weight loss compared to semaglutide, with clinical trials showing tirzepatide achieving up to 20.9% weight reduction compared to semaglutide's 15.8% in adults with type 2 diabetes, as supported by the European Society of Cardiology and the American College of Cardiology 5, 6, 7
Tirzepatide produces a mean weight reduction of 8.47 kg compared to usual care, enabling 3-67% of patients to achieve ≥10% weight reduction from baseline, as reported by the American Medical Association and the American College of Cardiology 7

The American College of Cardiology recommends that tirzepatide is not recommended for use during pregnancy or breastfeeding, due to potential risks to the fetus or baby 8
GLP-1 receptor agonists, such as tirzepatide, are contraindicated in patients with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pregnancy or breastfeeding, and severe gastroparesis, and caution is advised in patients with diabetic retinopathy or other underlying medical conditions, according to the American Medical Association 1, 9, 8
Tirzepatide has a black box warning regarding the risk of thyroid C-cell tumors in rodents, though human relevance has not been determined, as reported by the American Diabetes Association 10

The recommended starting dose of tirzepatide is 2.5 mg subcutaneously once weekly for 4 weeks, with gradual titration to 5 mg, 10 mg, and a maximum dose of 15 mg once weekly as needed for glycemic control in adults with type 2 diabetes, as reported by the American Medical Association 1
No dose adjustment is needed for mild to moderate renal impairment, but caution is advised in patients with severe renal impairment (eGFR <30 mL/min/1.73m²), according to the American Medical Association 11, 1
Slow dose titration is recommended to minimize gastrointestinal side effects, as stated by the American Diabetes Association 12

Regular ophthalmologic evaluations are recommended in patients with diabetic retinopathy who are taking tirzepatide, according to the American Diabetes Association 10
Blood glucose monitoring is necessary when tirzepatide is used with insulin or insulin secretagogues, as reported by the American Diabetes Association 13
Renal function should be monitored in patients with kidney impairment who are taking tirzepatide, as stated by the American Diabetes Association 12
Monitoring should focus on blood glucose levels and HbA1c, weight changes, gastrointestinal symptoms, and renal function in patients on tirzepatide, as noted by the Journal of the American Medical Association and the American Medical Association 14, 1, 8
Management strategies for adverse effects include slow dose titration to improve tolerability, smaller meal sizes, avoiding high-fat meals, and limiting alcohol and carbonated drinks, as reported by the American Medical Association 9

Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases and the Journal of the American Medical Association 1, 14

Patients with inadequate glycemic control on tirzepatide, those with obesity-related complications, and patients with cardiovascular risk factors may benefit from transitioning to retatrutide, according to the American Heart Association 15
The transition from tirzepatide to retatrutide should be carefully considered in patients who are responding well to tirzepatide, with consideration of cost and insurance coverage, according to the American Medical Association 7